SIGA Technologies, Inc.
4575 Research Way
2 articles with SIGA Technologies, Inc.
SIGA Enters into Cooperative Research and Development Agreement with U.S. Army Medical Research Institute of Infectious Disease to Evaluate the Efficacy of TPOXX® as a Post-Exposure Prophylactic for Smallpox
SIGA Technologies, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
Shares of Siga Technologies soared more than 11 percent late Friday after the company announced that its smallpox treatment Tpoxx was approved by the U.S. Food and Drug Administration.